Loading clinical trials...

Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

NCT04340362•Vertex Pharmaceuticals Incorporated

View on ClinicalTrials.gov

Summary

This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•APOL1 genotype of G1/G1, G2/G2, or G1/G2
•FSGS diagnosed by kidney biopsy

Exclusion Criteria

•Evidence of non-APOL1-mediated FSGS
•Participants with known sickle cell disease
•Solid organ or Bone marrow transplant

Locations (44)

University of Alabama at Birmingham - The Kirklin Clinic

Birmingham, Alabama, United States

California Institute of Renal Research

San Diego, California, United States

The George Washington University Medical Faculty Associates - Kidney Disease & Hypertension

Washington D.C., District of Columbia, United States

Howard University Hospital

Washington D.C., District of Columbia, United States

Kidney and Hypertension Specialists of Miami

Miami, Florida, United States

Florida Premier Research Institute

Winter Park, Florida, United States

Morehouse School of Medicine, Grady Memorial Hospital

Atlanta, Georgia, United States

Children's Healthcare of Atlanta

Atlanta, Georgia, United States

Georgia Nehphrology

Lawrenceville, Georgia, United States

Central Georgia Kidney Specialists PC

Macon, Georgia, United States

Key Dates

Start Date

June 8, 2020

Primary Completion Date

November 11, 2021

Completion Date

December 9, 2021

Last Updated

September 24, 2025

Enrollment

ACTUAL participants

Conditions

Glomerulosclerosis, Focal Segmental

Interventions

VX-147

DRUG

Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.

NCT05505500

Fluid OverloadGlomerulosclerosis, Focal Segmental+11 more

View study

TERMINATED

A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)

NCT04235621

Glomerulosclerosis, Focal SegmentalMinimal Change Disease+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

Inclusion Criteria

Exclusion Criteria

Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.

A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)

A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)